1446507-68-1

Basic information

• Product Name: 4-chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine
• Synonyms: 4-chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine
• CAS NO: 1446507-68-1
• Molecular Formula: C₁₅H₇ClF₆N₆
• Molecular Weight: 420.6996992
• Mol File: 1446507-68-1.mol

Chemical Properties

• Boiling Point: 514.5±60.0 °C(Predicted)
• Appearance: /
• Density: 1.582±0.06 g/cm3(Predicted)
• PKA: 1.47±0.38(Predicted)
• CAS DataBase Reference: 4-chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine(1446507-68-1)
• EPA Substance Registry System: 4-chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine(1446507-68-1)

Safety Data

• Hazardous Substances Data: 1446507-68-1(Hazardous Substances Data)

Usage

Uses

Used in Agricultural and Horticultural Applications:
4-Chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine is used as a herbicide for controlling weeds in various agricultural and horticultural settings. Its strong herbicidal activity and ability to inhibit the photosynthetic electron transport chain in target plants make it an effective tool for weed control, ensuring healthy crop growth and development.
It is important to follow safety guidelines when using and handling this chemical to minimize potential risks to human health and the environment.

Upstream product

• 189278-27-1 2-bromo-6-(trifluoromethyl)pyridine 
• 887583-52-0 6-(trifluoromethyl)pyridine-2-carbonitrile 
• 1446507-38-5 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4-(1H,3H)-dione 
• 155377-05-2 6-(trifluoromethyl)pyridine-2-carboxylic acid methyl ester 
• 131747-42-7 6-(trifluoromethyl)pyridine-2-carboxylic acid 
• 368-48-9 2-(trifluoromethyl)pyridine 
• 1446507-40-9 2,4-dichloro-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine 
• 147149-98-2 2-(trifluoromethyl)pyridin-4-amine 

Downstream Products

• 1446502-11-9 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol 

Relevant articles and documents

Compound with IDH mutant inhibitory activity, preparation method and application thereof

The invention belongs to the field of medicines, and particularly relates to a s-triazine compound with structural characteristics of a general formula I or a pharmaceutically acceptable salt thereof,a pharmaceutical composition and a preparation method thereof, and application of the s-triazine compound or the pharmaceutically acceptable salt and the pharmaceutical composition in preparation ofIDH2 mutant inhibitors. According to the invention, pharmacological experiment results show that the compound disclosed by the invention has an obvious inhibition effect on the activity of an IDH2 mutant (mIDH2), can effectively inhibit the process that alpha-ketoglutaric acid is catalyzed by mIDH2 to generate 2-hydroxyglutaric acid, and can be used for preparing drugs for preventing and/or treating various related diseases caused by IDH2 mutation, wherein the diseases comprise cancers carrying IDH2 mutation.

1,3,5-TRIAZINE DERIVATIVE SALT, CRYSTAL, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF

The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing t

Substituted triazine-based IDH inhibitor optical isomers and applications thereof

The present invention belongs to the field of medical chemistry, and relates to a class of substituted triazine-based IDH inhibitor optical isomers and applications thereof, and specifically providesoptical isomers represented by a formula I or formula II or hydrates, solvates, crystals or pharmaceutically acceptable salts thereof, and a preparation method thereof, a pharmaceutical composition containing the optical isomers or hydrates, solvates, crystals or pharmaceutically acceptable salts thereof, and uses in treatment of cancer characterized by the presence of mutant isocitrate dehydrogenase 2. According to the present invention, the compounds have good inhibitory activity against IDH2, and can be used as the cancer treatment agents with advantages of high treatment effect and low side effect. The formulas I and II are defined in the specification.

CHEMICAL COMPOUND OF ISOCITRATE DEHYDROGENASE INHIBITOR, AND APPLICATION THEREOF

Provided are a chemical compound of an isocitrate dehydrogenase inhibitor, and an application thereof, belonging to the field of medicinal chemistry; specifically provided is the chemical compound represented by formula I, or its isomer, pharmaceutically acceptable salt, crystal, solvate, or prodrug, as well as their preparation methods and pharmaceutical compositions containing said chemical compound, and an application of said chemical compound or composition. The chemical compound has very good ability to inhibit mutant IDH2 enzyme activity and to inhibit mutant IDH2 neoplastic cells, and may be used for preventing and/or treating a tumor characterized by the presence of mutant IDH2.

Crystal form of triazine IDH inhibitor methanesulfonate (by machine translation)

The invention belongs to the field, and relates to a crystal form of mesylate of IDH inhibitor and a preparation method, and particularly relates to a crystal form of methanesulfonate of (S)-3 - (trifluoromethyl) pyridin -1 -yl) 4 - (6 - (trifluoromethyl) pyridin -2 - amino) -6 - 2 -4 -triaz -1-yl) pyrrolidine 3 -3 -2 - 5 - alcohol and a preparation method thereof, wherein the mesylate crystal form can be used for preparing a medicament for treating cancers, and a preparation method thereof. (by machine translation)

Triazine compound, and preparation method and applications thereof

The invention belongs to the field of medicine chemistry, and more specifically relates to a triazine compound, a preparation method thereof, and applications of the triazine compound as a reference substance in (S)-3-(trifluoromethyl)-1-(4-(6-(trifluoromethyl)pyridine-2-yl)-6-(2-(trifluoromethyl)pyridine-4-amino)-1, 3, 5-triazine-2-yl)pyrrolidine-3-ol mesylate bulk drug quality study releated impurity qualitative and/or quantitative analysis.

Triazine IDH inhibitor pharmaceutical salt, and preparation method thereof

The invention belongs to the field of medicine chemistry, and relates to a triazine IDH inhibitor pharmaceutical salt or a hydrate, a solvate, or a crystal thereof, and a preparation method and applications, and more specifically relates to a pharmaceutic

Preparation method of triazine IDH inhibitor

The invention belongs to the field of medicine chemistry, and relates to a preparation method of a triazine IDH inhibitor, and more specifically relates to a preparation method of (S)-3-(trifluoromethyl)-1-(4-(6-(trifluoromethyl)pyridine-2-yl)-6-(2-(trifl

1, 3, 5-TRIAZINE DERIVATIVE AND METHOD OF USING SAME

Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.

TABLET COMPOSITIONS

Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt thereof.